Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts

Journal of Nuclear Medicine

Volumn 53, Issue 2, 2012, Pages 304-311

  Doleschel, Dennis ^a   Mundigl, Olaf ^b   Wessner, Axel ^b   Gremse, Felix ^a   Bachmann, Julie ^c   Rodriguez, Agustin ^c   Klingmüller, Ursula ^c   Jarsch, Michael ^b   Kiessling, Fabian ^a   Lederle, Wiltrud ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c GERMAN CANCER RESEARCH CENTER   (Germany)

Author keywords

CT, erythropoietin; Fluorescence molecular tomography; Molecular imaging; Oncology

Indexed keywords

ERYTHROPOIETIN RECEPTOR; HYDRAZIDE DERIVATIVE; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BINDING COMPETITION; BONE MARROW; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG RECEPTOR BINDING; DRUG TUMOR LEVEL; ENDOTHELIUM CELL; FEMALE; FLUORESCENCE IMAGING; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY; LIVER; LUNG NON SMALL CELL CANCER; MICRO-COMPUTED TOMOGRAPHY; MOLECULAR IMAGING; MOLECULAR PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; TISSUE DISTRIBUTION; TISSUE SECTION; TUMOR XENOGRAFT; URINARY EXCRETION;

ANIMALS; BONE MARROW; CARBOCYANINES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; ENDOTHELIAL CELLS; ERYTHROPOIETIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFRARED RAYS; LUNG NEOPLASMS; MICE; MOLECULAR IMAGING; MOLECULAR PROBES; RECEPTORS, ERYTHROPOIETIN; SUBSTRATE SPECIFICITY;

EID: 84856801469     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.091124     Document Type: Article

References (31)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Ott JJ, Ullrich A, Mascarenhas M, Stevens GA. Global cancer incidence and mortality caused by behavior and infection. J Public Health (Oxf). 2010;33:223-233.
3. Stoelben E, Huber RM, Müller RP, Wolf J. Multimodality therapy for lung cancer [in German]. Internist (Berl). 2010;51:1348-1357.
4. Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer. 2010;67:257-274.
5. Dempke W. Preclinical and clinical effects of erythropoietin in the management of anaemia in patients with non-small cell lung cancer. Anticancer Res. 2007;27:1745-1757. (Pubitemid 46954672)
6. Del Mastro L, Gennari A, Donati S. Chemotherapy of non-small-cell lung cancer: role of erythropoietin in the management of anemia. Ann Oncol. 1999;10 (suppl 5):S91-S94. (Pubitemid 29522791)
7. Cosaert J, Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer. 2002;87:825-833. (Pubitemid 35252956)
8. Tsiftsoglou AS, Vizirianakis IS, Strouboulis J. Erythropoiesis: model systems, molecular regulators, and developmental programs. IUBMB Life. 2009;61:800-830.
9. Spivak JL, Ferris DK, Fisher J, et al. Cell cycle-specific behavior of erythropoietin. Exp Hematol. 1996;24:141-150. (Pubitemid 26093881)
10. Becker V, Schilling M, Bachmann J, et al. Covering a broad dynamic range: information processing at the erythropoietin receptor. Science. 2010;328:1404-1408.
11. Kiss Z, Elliott S, Jedynasty K, Tesar V, Szegedi J. Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact. Eur J Clin Pharmacol. 2010;66:331-340.
12. Dagnon K, Pacary E, Commo F, et al. Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res. 2005; 11:993-999. (Pubitemid 40175746)
13. Hardee ME, Kirkpatrick JP, Shan S, et al. Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer. 2005;93:1350-1355. (Pubitemid 41752861)
14. Dunlop EA, Maxwell AP, Lappin TRJ. Impaired downregulation following erythropoietin receptor activation in non-small cell lung carcinoma. Stem Cells. 2007;25:380-384. (Pubitemid 46232792)
15. Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K, Arai H. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia. 2008;10:932-939.
16. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373:1532-1542.
17. Bohlius J, Tonia T, Schwarzer G. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients. Acta Haematol. 2011; 125:55-67.
18. Nowrousian MR, Dunst J, Vaupel P. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated. Strahlenther Onkol. 2008;184:121-136. (Pubitemid 351365785)
19. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol. 2008;67:39-61.
20. Elliott S, Busse L, Bass MB, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood. 2006;107:1892-1895. (Pubitemid 43289368)
21. Brown WM, Maxwell P, Graham AN, et al. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells. 2007;25:718-722. (Pubitemid 46354231)
22. Komatsu N, Adamson JW, Yamamoto K, et al. Erythropoietin rapidly induces tyrosine phosphorylation in the human erythropoietin-dependent cell line, UT-7. Blood. 1992;80:53-59.
23. Schilling M, Maiwald T, Bohl S, et al. Computational processing and error reduction strategies for standardized quantitative data in biological networks. FEBS J. 2005;272:6400-6411. (Pubitemid 41815627)
24. Inoue Y, Izawa K, Kiryu S, Tojo A, Ohtomo K. Diet and abdominal autofluorescence detected by in vivo fluorescence imaging of living mice. Mol Imaging. 2008;7:21-27.
25. Montet X, Ntziachristos V, Grimm J, Weissleder R. Tomographic fluorescence mapping of tumor targets. Cancer Res. 2005;65:6330-6336. (Pubitemid 40994419)
26. Lederle W, Linde N, Heusel J, et al. Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor- A-induced squamous cell carcinomas. Am J Pathol. 2010;176:981-994.
27. Agoram B, Aoki K, Doshi S, et al. Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: non-erythropoietin receptor-mediated pathways may play a major role. J Pharm Sci. 2009;98:2198-2211.
28. Sinclair AM, Coxon A, McCaffery I, et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood. 2010;115: 4264-4272.
29. Ntziachristos V, Ripoll J, Wang LV, Weissleder R. Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol. 2005;23:313-320. (Pubitemid 41094419)
30. 1H-MR spectroscopy. J Nucl Med. 2010;51:1676-1683.
31. Ntziachristos V, Bremer C, Graves EE, Ripoll J, Weissleder R. In vivo tomographic imaging of near-infrared fluorescent probes. Mol Imaging. 2002;1:82-88.